Structure Therapeutics Incorporation

Latest Results (12.10.2025):

Structure Therapeutics Incorporation reported its financial results for the second quarter of 2025, highlighting a strong cash position and increased investments in research and development to support its growth and clinical milestones. The company continues to advance its pipeline of oral small molecule therapeutics for metabolic diseases, particularly in obesity management.

Cash Position

As of June 30, 2025, Structure Therapeutics Inc. holds $786.5 million in cash, cash equivalents, and short-term investments. This robust financial standing is expected to fund projected operations and key clinical milestones through at least 2027, ensuring continued progress in their clinical programs.

R&D Expenses

Research and Development expenses for the second quarter of 2025 amounted to $54.7 million, a significant increase from $22.1 million in the same period of 2024. This rise is primarily due to expanded pre-clinical research, increased clinical trial costs, and higher personnel-related expenses to support the advancement of the company's GLP-1 receptor franchise, including aleniglipron.

G&A Expenses

General and Administrative expenses for the second quarter of 2025 were $15.7 million, up from $11.3 million in the second quarter of 2024. The increase is attributed to higher employee expenses as the company scales its infrastructure to support its growth as a publicly-traded entity.

Net Loss

The net loss for the second quarter of 2025 was $61.7 million, which includes a non-cash share-based compensation expense of $7.5 million. This is an improvement compared to a net loss of $26.0 million and a non-cash share-based compensation expense of $4.2 million in the second quarter of 2024.